1 August 2017 Evaluation of a novel photosensitizing drug having antitumor effect for advanced prostate cancer
Author Affiliations +
Abstract
Prostate cancer is the second most frequently diagnosed cancer among men worldwide and a novel treatment for the disease is required. Replication-deficient virus particles, hemagglutinating virus of Japan envelope (HVJ-E), has cytotoxicity to cancer cells. To enhance the therapeutic effect of HVJ-E by photodynamic therapy (PDT) as a trigger of HVJ-E’s anti-tumor effect, talaporfin sodium (Laserphyrin) used for PDT was encapsulated into HVJ-E to produce a novel photosensitizing drug, named Laserphyrin ®-HVJ-E, and its therapeutic effect for prostate cancer cells (PC-3) was evaluated. As the results, direct cytotoxicities of HVJ-E and Laserphyrin ®-HVJ-E for PC-3 after an administration time of 48 h were almost the same. Cell survival rates of PC-3, which were irradiated 2 h after administration of Laserphyrin ®-HVJ-E, were about 7.8%. Although further study is needed to find an optimal PDT condition, these results suggest that Laserphyrin ®-HVJ-E is useful for treatment of prostate cancer due to the combination of cytotoxicities of HVJ-E and PDT.
© (2017) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Sachiko Saito, Sachiko Saito, Mizuho Inai, Mizuho Inai, Norihiro Honda, Norihiro Honda, Hisanao Hazama, Hisanao Hazama, Yasufumi Kaneda, Yasufumi Kaneda, Kunio Awazu, Kunio Awazu, } "Evaluation of a novel photosensitizing drug having antitumor effect for advanced prostate cancer", Proc. SPIE 10417, Medical Laser Applications and Laser-Tissue Interactions VIII, 1041705 (1 August 2017); doi: 10.1117/12.2286071; https://doi.org/10.1117/12.2286071
PROCEEDINGS
5 PAGES


SHARE
Back to Top